Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 12/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | CCNK | O75909 | 1/20 | 0.31 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17778747 | 1.00 | WNT3A (0.35) | WNT3AMAPK14JAK2NTRK1MAPK1 | |
| SCHEMBL19689783 | 1.00 | WNT3A (0.35) | WNT3AMAPK14JAK2NTRK1MAPK1 | |
| SCHEMBL16754428 | 0.92 | PIK3CA (0.33) | MAPK14JAK2NTRK1 | |
| SCHEMBL16754426 | 0.92 | PIK3CA (0.33) | MAPK14JAK2NTRK1 | |
| SCHEMBL17768171 | 0.92 | KIF18A (0.36) | WNT3AMAPK14JAK2NTRK1MAPK1 | |
| SCHEMBL17768173 | 0.92 | KIF18A (0.36) | WNT3AMAPK14JAK2NTRK1MAPK1 | |
| SCHEMBL17778758 | 0.92 | KIF18A (0.36) | WNT3AMAPK14JAK2NTRK1MAPK1 | |
| SCHEMBL19689748 | 0.90 | MAPK14 (0.34) | WNT3AMAPK14JAK2NTRK1MAPK1 | |
| SCHEMBL17767935 | 0.90 | MAPK14 (0.34) | WNT3AMAPK14JAK2NTRK1MAPK1 | |
| SCHEMBL19689749 | 0.90 | MAPK14 (0.34) | WNT3AMAPK14JAK2NTRK1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | WNT3A 4482/4885MAPK14 1292/4885JAK2 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.